EP Patent

EP4046633A1 — The use of repirinast in the prophylaxis or treatment of renal fibrosis or kidney disease

Assigned to Algernon Pharmaceuticals Inc · Expires 2022-08-24 · 4y expired

What this patent protects

Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefyllne are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.

USPTO Abstract

Iguratimod, Repirinast, Lobenzarit, Actarit, Ifenprodil, Bemithyl, Bromantane, Emoxypine, Udenafil, and/or Istradefyllne are used for the treatment or prophylaxis of renal fibrosis, kidney disease, or chronic kidney disease in a subject.

Drugs covered by this patent

Patent Metadata

Patent number: EP4046633A1
Jurisdiction: EP
Classification: —
Expires: 2022-08-24
Drug substance claim: No
Drug product claim: No
Assignee: Algernon Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.